UBI Pharma has been growing earnings at an average annual rate of 66.9%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 10.3% per year. UBI Pharma's return on equity is 0.07%, and it has net margins of 0.1%.
Key information
66.95%
Earnings growth rate
67.03%
EPS growth rate
Biotechs Industry Growth
12.22%
Revenue growth rate
10.31%
Return on equity
0.069%
Net Margin
0.12%
Last Earnings Update
31 Dec 2023
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How UBI Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TPEX:6562 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 23
649
1
93
99
30 Sep 23
650
21
92
115
30 Jun 23
651
42
90
131
31 Mar 23
642
44
91
141
31 Dec 22
634
47
92
152
30 Sep 22
660
64
92
140
30 Jun 22
686
81
91
128
31 Mar 22
665
52
88
137
31 Dec 21
644
22
85
145
30 Sep 21
577
-1
107
149
30 Jun 21
510
-24
129
153
31 Mar 21
484
-49
140
145
31 Dec 20
458
-74
152
136
30 Sep 20
467
-149
137
167
30 Jun 20
476
-223
122
197
31 Mar 20
478
-233
127
205
31 Dec 19
480
-242
133
213
30 Sep 19
459
-242
129
220
30 Jun 19
438
-242
124
228
31 Mar 19
431
-241
107
239
31 Dec 18
424
-241
90
250
30 Sep 18
412
-213
81
220
30 Jun 18
400
-185
73
191
31 Mar 18
366
-176
66
179
31 Dec 17
333
-167
59
168
30 Sep 17
335
-204
55
206
30 Jun 17
337
-241
51
244
31 Mar 17
347
-233
52
243
31 Dec 16
358
-226
53
241
30 Sep 16
389
-135
54
187
30 Jun 16
421
-43
55
134
31 Mar 16
417
-21
54
106
31 Dec 15
413
2
54
78
31 Dec 14
409
39
42
29
Quality Earnings: 6562 has high quality earnings.
Growing Profit Margin: 6562's current net profit margins (0.1%) are lower than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6562 has become profitable over the past 5 years, growing earnings by 66.9% per year.
Accelerating Growth: 6562's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6562 had negative earnings growth (-98.3%) over the past year, making it difficult to compare to the Biotechs industry average (-8.8%).
Return on Equity
High ROE: 6562's Return on Equity (0.07%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/05/12 07:37
End of Day Share Price
2024/05/10 00:00
Earnings
2023/12/31
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UBI Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.